STLN · Starling Oncology, Inc. · Executive Compensation
$3.26
+0.06 (+1.88%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18
4.68M
Avg daily vol (3M)
2.45M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,934,930 |
| Yale Podnos | — | $775,905 |
| Robert Carter | — | $734,130 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,118,358 |
| Mihir Shah | — | $733,144 |
| Jeremy Castle | — | $622,220 |
| Yale Podnos | — | $610,332 |
| Robert Carter | — | $434,404 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $1,215,190 |
| Daniel Virnich | — | $808,129 |
| Mihir Shah | — | $801,743 |
| Yale Podnos | — | $591,284 |
| Jeremy Castle | — | $486,126 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $6,629,723 |
| Daniel Virnich | — | $3,244,461 |
| Mihir Shah | — | $2,264,237 |
| Yale Podnos | — | $1,249,186 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $11,635,536 |
| Daniel Virnich | — | $7,638,167 |
| Scott Dalgleish | — | $4,758,691 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $611,400 |
| Daniel Virnich | — | $418,684 |
| Scott Dalgleish | — | $317,583 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kimberly Tzoumakas | Director | Appointed | 2026-02-23 |
| Mark D. Stolper | Director | Appointed | 2026-01-07 |
|
Gabriel Ling
“Mr. Ling’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2025-12-01 |
| Anne McGeorge | Chair of the Board | Appointed | 2025-08-13 |
|
Richard Barasch
“Mr. Barasch’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chairman of the Board | Resigned | 2025-08-13 |
|
Jeremy Castle
“Mr. Castle’s resignation was not the result of any disagreement between Mr. Castle and the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Operating Officer | Resigned | 2025-05-07 |
|
Maeve O'Meara
“Ms. O’Meara’s resignation is not the result of a disagreement with the Company or the Company’s Board of Directors or of any matter relating to the Company’s operations, financial statements, policies or practices.”
|
director | Resigned | 2024-11-12 |
| Robert Carter | Chief Financial Officer | Appointed | 2024-09-23 |
| Robert Carter | principal accounting officer | Appointed | 2024-09-23 |
|
Mihir Shah
“His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.”
|
principal accounting officer | Resigned | 2024-09-23 |
|
Mihir Shah
“His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.”
|
Chief Financial Officer | Resigned | 2024-09-23 |
| Jeremy N. Castle | Chief Operations Officer | Appointed | 2023-09-06 |
|
Ravi Sarin
“Mr. Sarin’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
director of the Board | Resigned | 2023-09-01 |
| Daniel Virnich | Chief Executive Officer | Appointed | 2023-06-12 |
|
Brad Hively
“Mr Hively’s resignation was not the result of any disagreement between Mr. Hively and the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Executive Officer | Resigned | 2023-06-12 |
| Matthew Miller, M.D. | Chief Operating Officer | Terminated | 2023-05-22 |
| Diona Simoneit | Chief Accounting Officer and principal accounting officer | Resigned | 2022-12-01 |
| Gabriel Ling | Board | Appointed | 2022-09-22 |
| Mark Pacala | Board | Appointed | 2022-09-22 |
| Diona Simoneit | principal accounting officer | Appointed | 2022-04-04 |
| Mihir Shah | Chief Financial Officer | Appointed | 2022-04-04 |
| Matt Miller | Chief Operating Officer | Appointed | 2022-03-07 |
| Matthew Miller | Chief Operating Officer | Appointed | 2022-03-07 |
| Daniel Virnich | President | Appointed | 2022-03-07 |
| Ravi Sarin | Director | Appointed | 2021-11-18 |
Leadership
- Brad Hively CEO, Chairman
- Daniel Virnich CEO, COO, Board Member
- Anne McGeorge Chairman
- Richard Barasch Chairman, Board Member
- Mihir Shah CFO
- Robert Carter CFO, Chief Accounting Officer
- Dr. Matt Miller COO
- Jeremy N. Castle COO
- Matt Miller COO
- Matthew Miller COO
- Mark Huppelsheuser General Counsel
- Diona Simoneit Chief Accounting Officer
- Dr. Mohit Kaushal Board Member
- Gabriel Ling Board Member
- Karen Johnson Board Member
- Kimberly Tzoumakas Board Member
- Maeve O’Meara Board Member
- Mark D. Stolper Board Member
- Mark Pacala Board Member
- Mark Stolper Board Member
- Mohit Kaushal Board Member
- Ravi Sarin Board Member
Key facts
CIK
1799191
CUSIP
68236X100
13F (30d)
140 filings
127 filers
Visit website
Investor relations